Jan Holmgren

Summary

Country: Sweden

Publications

  1. pmc Cholera toxin - a foe & a friend
    Joaquin Sanchez
    University of Gothenburg Vaccine Research Institute GUVAX and Department of Microbiology and Immunology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    Indian J Med Res 133:153-63. 2011
  2. doi request reprint Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered al
    J Holmgren
    University of Gothenburg Vaccine Research Institute GUVAX, Department of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
    Vaccine 31:2457-64. 2013
  3. doi request reprint Vaccines against mucosal infections
    Jan Holmgren
    University of Gothenburg Vaccine Research Institute GUVAX and Department of Microbiology and Immunology, the Sahlgrenska Academy at University of Gothenburg, Sweden
    Curr Opin Immunol 24:343-53. 2012
  4. ncbi request reprint Mucosal immunity and vaccines
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute, Goteborg University, SE 405 30 Goteborg, Sweden
    Nat Med 11:S45-53. 2005
  5. ncbi request reprint Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, P O Box 435, SE 40530 Goteborg, Sweden
    Immunol Lett 97:181-8. 2005
  6. ncbi request reprint Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
    Jan Holmgren
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Goteborg University, Sweden
    Expert Rev Vaccines 2:205-17. 2003
  7. ncbi request reprint Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges
    Jan Holmgren
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Sweden
    Vaccine 21:S89-95. 2003
  8. ncbi request reprint B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit
    Jia Bin Sun
    Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute, Institute of Biomedicine Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Immunol 181:8278-87. 2008
  9. ncbi request reprint Differential expression of intestinal membrane transporters in cholera patients
    Carl Fredrik Flach
    Institute of Biomedicine, Department of Microbiology and Immunology, and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Goteborg, Sweden
    FEBS Lett 581:3183-8. 2007
  10. ncbi request reprint Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells
    Jia Bin Sun
    Department of Microbiology and Immunology, Institute of Biomedicine and Göteborg University Vaccine Research Institute, Sahlgrenska Academy at Goteborg University, 405 30 Goteborg, Sweden
    J Immunol 177:7634-44. 2006

Research Grants

Collaborators

Detail Information

Publications63

  1. pmc Cholera toxin - a foe & a friend
    Joaquin Sanchez
    University of Gothenburg Vaccine Research Institute GUVAX and Department of Microbiology and Immunology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    Indian J Med Res 133:153-63. 2011
    ..In summary, in the 50 years after De΄s discovery of CT, this molecule has emerged from being the cholera patient΄s "foe" to also becoming a highly useful scientist΄s "friend"...
  2. doi request reprint Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered al
    J Holmgren
    University of Gothenburg Vaccine Research Institute GUVAX, Department of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
    Vaccine 31:2457-64. 2013
    ..We conclude that the new multivalent oral ETEC vaccine, both alone and especially in combination with the dmLT adjuvant, shows great promise for further testing in humans...
  3. doi request reprint Vaccines against mucosal infections
    Jan Holmgren
    University of Gothenburg Vaccine Research Institute GUVAX and Department of Microbiology and Immunology, the Sahlgrenska Academy at University of Gothenburg, Sweden
    Curr Opin Immunol 24:343-53. 2012
    ..Research is needed to define the impact of factors such as malnutrition, aberrant intestinal microflora, concomitant infections, and preexisting immunity as well as of host genetic factors on the immunogenicity of these vaccines...
  4. ncbi request reprint Mucosal immunity and vaccines
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute, Goteborg University, SE 405 30 Goteborg, Sweden
    Nat Med 11:S45-53. 2005
    ..Here we review the properties of the mucosal immune system and discuss advances in the development of mucosal vaccines for protection against infections and for treatment of various inflammatory disorders...
  5. ncbi request reprint Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, P O Box 435, SE 40530 Goteborg, Sweden
    Immunol Lett 97:181-8. 2005
    ..The properties and clinical potential of these different classes of adjuvants are being discussed...
  6. ncbi request reprint Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
    Jan Holmgren
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Goteborg University, Sweden
    Expert Rev Vaccines 2:205-17. 2003
    ....
  7. ncbi request reprint Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges
    Jan Holmgren
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Sweden
    Vaccine 21:S89-95. 2003
    ....
  8. ncbi request reprint B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit
    Jia Bin Sun
    Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute, Institute of Biomedicine Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Immunol 181:8278-87. 2008
    ....
  9. ncbi request reprint Differential expression of intestinal membrane transporters in cholera patients
    Carl Fredrik Flach
    Institute of Biomedicine, Department of Microbiology and Immunology, and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Goteborg, Sweden
    FEBS Lett 581:3183-8. 2007
    ..The majority of these changes appear to be attempts of the host to counteract the secretory response. Our results also support the concept that epithelial cells are involved in 5-HT signalling during acute cholera...
  10. ncbi request reprint Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells
    Jia Bin Sun
    Department of Microbiology and Immunology, Institute of Biomedicine and Göteborg University Vaccine Research Institute, Sahlgrenska Academy at Goteborg University, 405 30 Goteborg, Sweden
    J Immunol 177:7634-44. 2006
    ....
  11. doi request reprint Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice
    Joshua Tobias
    University of Gothenburg Vaccine Research Institute, and WHO Collaborating Center for Research on Enterotoxigenic Escherichia coli, Department of Microbiology and Immunology, The Sahlgrenska Academy of University of Gothenburg, S 40530 Gothenburg, Sweden
    Vaccine 29:8863-9. 2011
    ..Our data indicate that the described phenol-inactivated non-toxigenic and CS6 over-expressing E. coli strain may be a useful component in an oral ETEC vaccine...
  12. doi request reprint CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization
    Linda Fahlén-Yrlid
    Department of Microbiology and Immunology, Institute of Biomedicine, The Mucosal Immunobiology and Vaccine Center, University of Gothenburg Vaccine Research Institute, Goteborg, Sweden
    J Immunol 183:5032-41. 2009
    ..This study therefore demonstrates that cDCs are required for successful mucosal immunization, unless a very high dose of Ag is administered...
  13. pmc Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach
    Sukanya Raghavan
    University of Gothenburg Vaccine Research Institute, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    Infect Immun 78:4251-60. 2010
    ..We conclude that, in mice, SL immunization can effectively induce protection against H. pylori infection in association with strong T and B cell infiltration into the stomach...
  14. doi request reprint A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori
    Carl Fredrik Flach
    Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute, Gothenburg, Sweden
    Vaccine 29:1235-41. 2011
    ..In conclusion, HpaA(trunc) is a promising, readily produced, non-toxic recombinant antigen for inclusion in a mucosal vaccine against H. pylori infection, which may preferably be given sublingually together with UreB...
  15. doi request reprint Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria
    Joshua Tobias
    University of Gothenburg Vaccine Research Institute, Department of Microbiology and Immunology, The Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden
    Vaccine 28:6977-84. 2010
    ..We conclude that the described type of recombinant bacteria over-expressing major CFs of ETEC, alone or in combination, may be useful as candidate strains for use in an oral whole-cell CF-ETEC vaccine...
  16. doi request reprint The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells
    Petra Henning
    Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    Eur J Immunol 41:2185-96. 2011
    ..However, the direct transduction of conventional DCs is not essential. These findings have important implications for the improvement of Ad vector design and vaccine-induced mucosal immunity...
  17. doi request reprint CD8- natural killer cells are greatly enriched in the human gastrointestinal tract and have the capacity to respond to bacteria
    Asa Lindgren
    Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden asa lindgren microbio gu se
    J Innate Immun 2:294-302. 2010
    ..These findings may have important implications for the understanding of NK cell subsets and the innate defense against gastrointestinal bacterial infections...
  18. pmc Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells
    Annie George Chandy
    Göteborg University Vaccine Research Institute GUVAX and Department of Medical Microbiology and Immunology, Goteborg University, Goteborg, Sweden
    Immunology 118:311-20. 2006
    ..Thus, several mechanisms might co-orchestrate the systemic tolerance seen in response to feeding with CTB-coupled antigen...
  19. pmc A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection
    Louise Sjökvist Ottsjö
    Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
    Infect Immun 81:1532-40. 2013
    ..pylori antigens. Our results suggest that dmLT is an attractive adjuvant for inclusion in a mucosal vaccine against H. pylori infection...
  20. doi request reprint Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice
    Carl Fredrik Flach
    Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
    Vaccine 30:1636-43. 2012
    ..We have studied the chemokines and chemokine receptors guiding infection- and vaccination-induced immune cells to the stomach and their relation to protection against H. pylori infection in mice...
  21. doi request reprint Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens
    Michael Lebens
    Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute, Institute of Biomedicine, University of Gothenburg, Box 435, SE 405 30 Goteborg, Sweden
    Vaccine 29:7505-13. 2011
    ..We propose that such a strain may form the basis of a single strain killed whole cell cholera vaccine protecting against cholera caused by either the Inaba or Ogawa serotype of V. cholerae O1...
  22. pmc Broad up-regulation of innate defense factors during acute cholera
    Carl Fredrik Flach
    Institute of Biomedicine, Department of Microbiology and Immunology, Goteborg University, Box 435, 40530 Goteborg, Sweden
    Infect Immun 75:2343-50. 2007
    ..Both direct effects of CT on the epithelial cells and changes in the lamina propria cells contribute to this up-regulation...
  23. ncbi request reprint Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor
    Kristina Eriksson
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Gothenberg, Sweden
    Eur J Immunol 34:1272-81. 2004
    ..These results have interesting implications for DC vaccination aimed at inducing CTL immune responses...
  24. doi request reprint Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccines
    Joshua Tobias
    University of Gothenburg Vaccine Research Institute GUVAX, 40530 Gothenburg, Sweden
    Appl Microbiol Biotechnol 87:1355-65. 2010
    ..Bacteria expressing hybrid fimbriae are potential candidate strains in an oral-killed CF-ETEC vaccine, and the approach represents an attractive and novel means of producing a broad-spectrum ETEC vaccine...
  25. doi request reprint Impaired IFN-γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients
    Asa Lindgren
    Institute of Biomedicine, Department of Microbiology and Immunology, and Mucosal Immunobiology and Vaccine Institute for Strategic Research, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
    Exp Cell Res 317:849-58. 2011
    ..In addition, we propose that the observed suppression is due to tumour-derived TGF-β and that increased expression of the transcription factor GATA-3 may be responsible for the TGF-β induced suppression...
  26. ncbi request reprint Recent advances in mucosal vaccines and adjuvants
    Kristina Eriksson
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Guldhedsgatan 10A, 413 46 Goteborg, Sweden
    Curr Opin Immunol 14:666-72. 2002
    ..However, there have also been failures, such as the withdrawal of an oral vaccine against rotavirus diarrhea and a nasal vaccine against influenza, because of their potential side effects...
  27. ncbi request reprint Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin
    Jenni Adamsson
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Goteborg University, Goteborg, Sweden
    J Immunol 176:4902-13. 2006
    ..To our knowledge, CTB is the first nontoxic derivative of microbial toxins discovered that when chemically linked to CpG remarkably augments the CpG-mediated immune responses...
  28. doi request reprint Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae
    Erik Nygren
    Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
    Vaccine 26:6784-90. 2008
    ..cholerae. The established immunization protocols will allow evaluation of the systemic and mucosal immunogenicity of new vaccine formulations...
  29. ncbi request reprint CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tactics
    Ali M Harandi
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Medicinaregatan 7A, 405 30 Goteborg, Sweden
    Vaccine 24:S2-48-9. 2006
    ..Interestingly, we could show that the immunostimulatory effect of CpG DNA is much improved when chemically conjugated to the non-toxic B subunit of cholera toxin...
  30. ncbi request reprint A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection
    Michael Lebens
    Department of Medical Microbiology and Immunology, Göteborg University and the Göteborg University Research Institute, Guldhedsgatan 10A, SE 413 46, Goteborg, Sweden
    Vaccine 21:514-20. 2003
    ..The results suggest that this type of hybrid protein could be used as a combined anti-immunopathology and anti-infection vaccine against schistosomiasis...
  31. ncbi request reprint Current status and future prospects for a vaccine against schistosomiasis
    Michael Lebens
    Goteborg University, Department of Medical Microbiology and Immunology, PO Box 435, SE 405 30 Gothenburg, Sweden
    Expert Rev Vaccines 3:315-28. 2004
    ..This review summarizes the life-cycle of the parasite, current knowledge of pathogenesis and acquired immunity based on animal studies and observations in humans and the status of efforts in the vaccine development field...
  32. ncbi request reprint CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice
    Sara Tengvall
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Medicinaregatan 7A, 405 30 Goteborg, Sweden
    J Reprod Immunol 68:53-69. 2005
    ..These findings emphasize the value of using CpG ODN in a DNA vaccination scheme against genital herpes and merit also further evaluation in genetic vaccination approaches against other sexually transmitted infections...
  33. pmc Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development
    Kristina Eriksson
    Department of Medical Microbiology and Immunology, Box 435, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, 405 30 Goteborg, Sweden
    Infect Immun 71:1740-7. 2003
    ..These results imply that CT and CTB can be used to both markedly increase and partially direct the DC vaccine-induced immune response with respect to Th1 and Th2 responses, which has obvious implications for DC-based vaccine development...
  34. ncbi request reprint Recent developments in mucosal immunomodulatory adjuvants
    Ali M Harandi
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Guldhedsgatan 10A, 413 46 Goteborg, Sweden
    Curr Opin Investig Drugs 4:156-61. 2003
    ..These agents hold much promise as useful mucosal immunomodulators/adjuvants for induction of strong innate immune response and also for subsequent development of specific acquired immunity against mucosal pathogens...
  35. doi request reprint Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation
    Annika Borde
    Pharmaceutical Technology, Chemical and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
    Eur J Pharm Biopharm 79:508-18. 2011
    ..Thus, we present a process generating a dry oral inactivated whole-cell cholera vaccine formulation with attractive features for public health use in cholera-afflicted settings...
  36. ncbi request reprint CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections
    Ali M Harandi
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute GUVAX, Goteborg University, Medicinaregatan 7A, 40530 Goteborg, Sweden
    Curr Opin Investig Drugs 5:141-5. 2004
    ..In this review, recent developments in the use of CpG DNA for inducing immunity in the mucosal tissues will be highlighted...
  37. ncbi request reprint Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination
    Joaquin Sanchez
    Department of Medical Microbiology and Immunology, Göteborg University and the Göteborg University Vaccine Research Institute, Guldhedsgatan 10A, Göteborg SE 413 46, Sweden
    J Biol Chem 277:33369-77. 2002
    ..The simplicity of the procedure, combined with efficient expression and assembly of derivatives, suggests this approach could allow for large scale production of detoxified, yet immunologically active CT molecules...
  38. pmc A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection
    Ali M Harandi
    Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Goteborg University, Sweden
    J Virol 77:953-62. 2003
    ....
  39. pmc Expression of cholera toxin under non-AKI conditions in Vibrio cholerae El Tor induced by increasing the exposed surface of cultures
    Joaquin Sanchez
    Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Cuernavaca, Mexico
    J Bacteriol 186:1355-61. 2004
    ..The expression of key genes involved in the regulation of CT production was analyzed, and we found that the expression pattern closely resembles the in vivo expression pattern...
  40. pmc Cholera toxin induces a transient depletion of CD8+ intraepithelial lymphocytes in the rat small intestine as detected by microarray and immunohistochemistry
    Carl Fredrik Flach
    Department of Medical Microbiology and Immunology, Goteborg University, 40530 Goteborg, Sweden
    Infect Immun 73:5595-602. 2005
    ....
  41. pmc Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo
    Hamid Sadeghi
    Department of Medical Microbiology and Immunology, University of Goteborg, Goteborg, Sweden
    Immunology 106:237-45. 2002
    ..In addition, we demonstrate that the CI fusion protein induces efficient immunosuppression after oral administration, raising the possibility of using such constructs in the treatment of type-1 diabetes...
  42. ncbi request reprint CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and disease
    Sukanya Raghavan
    Department of Medical Microbiology and Immunology, The Göteborg University Vaccine Research Institute GUVAX, P O Box 435, 405 30 Goteborg, Sweden
    FEMS Immunol Med Microbiol 44:121-7. 2005
    ..pylori-infected individuals to develop duodenal ulcers...
  43. pmc Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production
    Cheol H Yun
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Institute GUVAX, Goteborg University, Box 435, 40530 Goteborg, Sweden
    Infect Immun 73:1482-90. 2005
    ..pylori antigen and IL-12. We propose that NK cells play an active role in the local immune response to H. pylori infection...
  44. ncbi request reprint Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin
    Carmelo Luci
    Institut National de la Sante et de la Recherche Medicale INSERM, Unité Mixte de Recherche UMR 721, Faculté de Médecine Pasteur, Nice, France
    J Immunol 176:2749-57. 2006
    ..These results demonstrate that CTB is an efficient adjuvant-delivery system for DC-mediated induction of genital CTL responses and may have implications for the design of vaccines against sexually transmitted infections...
  45. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
    ..The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated...
  46. pmc Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh
    G Balakrish Nair
    Laboratory Sciences Division, ICDDR, B Centre for Health and Population Research, Mohakhali, Dhaka 1212, Bangladesh
    J Clin Microbiol 44:4211-3. 2006
    ..All of the El Tor strains of V. cholerae O1 isolated since 2001 produced CT of the classical biotype, while those isolated before 2001 produced CT of the El Tor biotype...
  47. ncbi request reprint In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin
    Fabienne Anjuere
    Institut National de la Sante et de la Recherche Medicale, Institut Fédératif de Recherche, Faculté de Médecine Pasteur, Nice, France
    J Immunol 173:5103-11. 2004
    ....
  48. ncbi request reprint Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method
    John Clemens
    International Vaccine Institute, Seoul, Korea
    J Infect Dis 189:2299-307. 2004
    ....
  49. ncbi request reprint Sublingual immunization induces broad-based systemic and mucosal immune responses in mice
    Nicolas Cuburu
    Institut National de la Sante et de la Recherche Medicale INSERM, Unité Mixte de Recherche UMR 721, Universite de Nice Sophia Antipolis, Nice, France
    Vaccine 25:8598-610. 2007
    ..These features underscore the potential of the s.l. mucosa to serve as an alternative vaccine delivery route...
  50. ncbi request reprint Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit
    Paula A Phipps
    Peter Gorer Department of Immunobiology, Guy s, King s and St Thomas School of Medicine and Dentistry, Guy s Hospital, London, GB
    Eur J Immunol 33:224-32. 2003
    ..We suggest that mucosally induced uveitis can be prevented by oral administration of the peptide-rCTB conjugate...
  51. pmc Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection
    Charlotte Larsson
    Department of Medical Microbiology, Dermatology and Infection, Lund University, Lund, Sweden
    Infect Immun 72:1184-7. 2004
    ..These findings have implications for the development of a human GBS vaccine...
  52. ncbi request reprint Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses
    Fabienne Anjuere
    Institut National de la Sante et de la Recherche Medicale, Nice, France
    J Immunol 170:1586-92. 2003
    ....
  53. ncbi request reprint Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin
    Salma Nowroozalizadeh
    Department of Virology, Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden
    Curr HIV Res 6:230-8. 2008
    ..These results have implications for the development of novel intervention strategies to prevent HIV infection...
  54. ncbi request reprint Diminished immunopathology in Schistosoma mansoni infection following intranasal administration of cholera toxin B-immunodominant peptide conjugate correlates with enhanced transforming growth factor-beta production by CD4 T cells
    Hector J Hernandez
    Department of Pathology, Tufts University School of Medicine, Boston, MA 02111, USA
    Parasite Immunol 24:423-7. 2002
    ..n. administration of a single immunodominant peptide conjugated to CTB can lead to down-regulation of the hepatic immunopathology associated with schistosomiasis, and that this down-regulation is, at least in part, mediated by TGF-beta...
  55. ncbi request reprint Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    Lancet 366:44-9. 2005
    ..We reanalysed data from a field trial in Bangladesh to ascertain whether there is evidence of indirect protection from killed oral cholera vaccines...
  56. ncbi request reprint Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea
    Joaquin Sanchez
    Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Av Universidad 1001, Col Chamilpa, CP62210, Cuernavaca, Morelos, Mexico
    Curr Opin Immunol 17:388-98. 2005
    ..Finally, the strong herd immunity elicited by an oral cholera vaccine indicates that cholera vaccination could have a significant public health impact...
  57. ncbi request reprint Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam
    Vu Dinh Thiem
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 24:4297-303. 2006
    ..The overall vaccine effectiveness 3-5 years after vaccination was 50% (9-63%). This low-cost, easily administered vaccine should be considered as a tool for the control of cholera...
  58. ncbi request reprint Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults
    Dang Duc Anh
    National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
    Vaccine 25:1149-55. 2007
    ..We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic...
  59. ncbi request reprint Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4
    Vu Dinh Thiem
    Vaccine 25:7981-3. 2007
  60. doi request reprint Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies
    Maria Lidqvist
    Fujirebio Diagnostics AB, Majnabbe Terminal, SE 414 55 Gothenburg, Sweden
    J Immunol Methods 337:88-96. 2008
    ..The combination of different phage display techniques for immunization and epitope mapping was efficient for generation and characterization of highly specific MAbs...
  61. ncbi request reprint [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge]
    Ake Sjoholm
    Karolinska Institutet, Diabetescentrum, Södersjukhuset AB, Stockholm
    Lakartidningen 105:1310, 1312. 2008
  62. pmc A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India
    Dilip Mahalanabis
    Society for Applied Studies, Kolkata, India
    PLoS ONE 3:e2323. 2008
    ..This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India...
  63. ncbi request reprint Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission
    Mohammad Ali
    International Vaccine Institute, Seoul, Korea
    Pediatr Infect Dis J 27:33-7. 2008
    ..We investigated whether mass immunization of older children and adults can confer herd protection to children too young to be vaccinated...

Research Grants2